title: Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
authors.forename: Nischala
authors.initials: N
authors.lastname: Ammannagari
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Celotto
authors.affiliation: Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY.
authors.forename: Vishala
authors.initials: V
authors.lastname: Neppalli
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
authors.forename: Kelvin
authors.initials: K
authors.lastname: Lee
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: sarah.holstein@roswellpark.org.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Holstein
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000145:classification / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D009361:Neoplasm Invasiveness; D011379:Prognosis; D035703:Therapies, Investigational / Q000379:methods; D017211:Treatment Failure
keywords: AMM; Central nervous system involvement; Extramedullary myeloma; Immunomodulatory drug; Proteasome inhibitor